drugset / Trial / NCT00875654
Intravenous Stem Cells After Ischemic Stroke
Phase 2
Completed
31 enrolled
University Hospital, Grenoble
Commissariat A L'energie Atomique · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the study is to evaluate feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells for patients presenting an ischemic stroke (less than 6 weeks).
Timeline
- Start
- 2010-08
- Primary completion
- 2017-10-20
- Completion
- 2017-10-20
Publications
- Jaillard A, Hommel M, Moisan A, Zeffiro TA, Favre-Wiki IM, Barbieux-Guillot M, Vadot W, Marcel S, Lamalle L, Grand S, Detante O; (for the ISIS-HERMES Study Group). Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial. Transl Stroke Res. 2020 Oct;11(5):910-923. doi: 10.1007/s12975-020-00787-z. Epub 2020 May 27.
- Hannanu FF, Goundous I, Detante O, Naegele B, Jaillard A. Spatiotemporal patterns of sensorimotor fMRI activity influence hand motor recovery in subacute stroke: A longitudinal task-related fMRI study. Cortex. 2020 Aug;129:80-98. doi: 10.1016/j.cortex.2020.03.024. Epub 2020 Apr 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous mesenchymal stem cells | Cell therapy | — | Intravenous |